-+ 0.00%
-+ 0.00%
-+ 0.00%

Shattuck Labs posts SL-325 Phase 1 data presentation, outlines DR3 antibody pipeline update

PUBT·06/08/2026 13:03:09
Listen to the news
Shattuck Labs posts SL-325 Phase 1 data presentation, outlines DR3 antibody pipeline update
  • Shattuck Labs posted Phase 1 results for SL-325, a DR3-blocking monoclonal antibody aimed at inflammatory bowel disease.
  • Healthy-volunteer study (NCT07158437) showed SL-325 was well tolerated across doses, with no serious adverse events reported.
  • Pharmacodynamic readout showed full DR3 occupancy at 0.1 mg/kg, with TL1A-binding blockade lasting months at doses of 1 mg/kg or higher.
  • Immunogenicity was low, with a 3.7% anti-drug antibody rate, with no reported impact on pharmacokinetics or receptor occupancy.
  • Shattuck plans to start a Phase 2b Crohn’s disease study in Q3 2026, with 12-week induction data targeted for 1H 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.